This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Okuma, K.
Right arrow Articles by Rose, J. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Okuma, K.
Right arrow Articles by Rose, J. K.

 Previous Article  |  Next Article 

Journal of Virology, August 2003, p. 8562-8569, Vol. 77, No. 15
0022-538X/03/$08.00+0     DOI: 10.1128/JVI.77.15.8562-8569.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Development of a Novel Surrogate Virus for Human T-Cell Leukemia Virus Type 1: Inhibition of Infection by Osteoprotegerin

Kazu Okuma,* Kevin P. Dalton,{dagger} Linda Buonocore, Elizabeth Ramsburg, and John K. Rose*

Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06520

Received 16 January 2003/ Accepted 3 May 2003

To develop a high-titer surrogate virus for human T-cell leukemia virus type 1 (HTLV-1), we generated recombinant vesicular stomatitis viruses (VSVs) in which the gene encoding the single transmembrane glycoprotein (G) was deleted. Genes encoding HTLV-1 envelope glycoproteins (HTEnv) or HTEnvG hybrid proteins were then inserted into either of two different sites in the VSV genome. The viruses also encoded a green fluorescent protein. With this surrogate virus, we found that a soluble protein, osteoprotegerin (OPG), or an OPG/Fc chimeric protein inhibited the infection of various cell lines. Our experiments indicate that this inhibition resulted from binding of heparan sulfate by OPG.

* Corresponding author. Mailing address: Department of Pathology (BML 342), Yale University School of Medicine, 310 Cedar St., New Haven, CT 06520-8023. Phone: (203) 785-6184. Fax: (203) 785-7467. E-mail: john.rose{at}yale.edu.

{dagger} Present address: School of Animal and Microbial Sciences, University of Reading, Reading RG6 6AJ, United Kingdom.

Journal of Virology, August 2003, p. 8562-8569, Vol. 77, No. 15
0022-538X/03/$08.00+0     DOI: 10.1128/JVI.77.15.8562-8569.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Jones, K. S., Petrow-Sadowski, C., Bertolette, D. C., Huang, Y., Ruscetti, F. W. (2005). Heparan Sulfate Proteoglycans Mediate Attachment and Entry of Human T-Cell Leukemia Virus Type 1 Virions into CD4+ T Cells. J. Virol. 79: 12692-12702 [Abstract] [Full Text]  
  • Jones, K. S., Akel, S., Petrow-Sadowski, C., Huang, Y., Bertolette, D. C., Ruscetti, F. W. (2005). Induction of Human T Cell Leukemia Virus Type I Receptors on Quiescent Naive T Lymphocytes by TGF-{beta}. J. Immunol. 174: 4262-4270 [Abstract] [Full Text]  
  • Roberts, A., Reuter, J. D., Wilson, J. H., Baldwin, S., Rose, J. K. (2004). Complete Protection from Papillomavirus Challenge after a Single Vaccination with a Vesicular Stomatitis Virus Vector Expressing High Levels of L1 Protein. J. Virol. 78: 3196-3199 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»